CSIMarket
 
Alzamend Neuro Inc   (ALZN)
 

The emerging corporation from the Major Pharmaceutical Preparations industry the ALZN released the fiscal time-frame ending third quarter of 2023, earnings

Alzamend Neuro Inc announced third quarter of 2023 operating loss of $-5.423512 millions


Published Mar 16 2023
CSIMarket Team / CSIMarket.com


Dryvax_pd The Major Pharmaceutical Preparations sector experts start to digest the third quarter of 2023 performance. Now they observe operating loss of $-5.423512 millions, from the company, as it has not cited any revenue yet, for the respective November to January 31 2023 financial reporting period.

In the most recent coming span of the corporation, the markets hope for additional business strategy to come as soon as probable. The markets are less interested in the prevailing organizational and operational excellence of the Major Pharmaceutical Preparations company.


It is not really a surprise, that the rising firm reported a shortfall of $-5.426 millions, which has widen from $-2.573 millions, in the similar period a year prior.


Alzamend Neuro Inc is expected to report next financial earnings on July 18, 2023.



Alzamend Neuro Inc's Price to earnings ratio PE

Alzamend Neuro Inc's Dividend Comparisons



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com